STRO May 2024 7.500 put
| Previous close | 3.5000 |
| Open | 3.5000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 7.50 |
| Expiry date | 2024-05-17 |
| Day's range | 3.5000 - 3.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
GlobeNewswireSutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with bevacizumab; enrollment is expected to complete in the first half of 2024 - - The randomized portion of REFRαME-O1, the registration-enabling study of luvelta for patients with platinum-resistant ovarian cancer, is
ZacksAnalysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
Sutro Biopharma (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.The past three years for Sutro Biopharma (NASDAQ:STRO) investors has not been profitable
Every investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So...
